AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc.

AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc.

E.D. Pa. (2003)

Fitzpatrick Wins Final Judgment On Behalf of Client AstraZeneca Against Mutual Pharmaceuticals

Fitzpatrick on behalf of its client AstraZeneca, won summary judgment of validity against Mutual Pharmaceutical Co., Inc.. Judge Baylson of the United States District Court for the Eastern District of Pennsylvania, concluded that AstraZeneca’s formulation patent for Plendil®, a treatment for high blood pressure and angina pectoris, was not invalid. The Court entered final judgment in favor of AstraZeneca. Earlier this year, Judge Baylson had granted AstraZeneca’s motion for summary judgment that Mutual Pharmaceuticals infringed AstraZeneca’s patent.

View Attachment (PDF)